News

The researchers noted that their paper is the first, to their knowledge, to report on a case of thrombocytopenic purpura (TTP) in a patient with metastatic renal cell carcinoma (RCC).
A secondary analysis of the EVEREST trial found that adjuvant everolimus did not provide a recurrence-free or overall survival benefit in patients with localized non–clear cell RCC.